3 articles
Italian drugmaker Recordati reported an 8.8% rise in first-half core profit to €540.2 million, driven by its rare diseases segment. Its board deemed a €10.7 billion takeover offer fair, despite dissen
Recordati's board voted 6-4 to accept CVC and GBL's €10.7 billion takeover offer as fair, despite four independent directors dissenting over valuation concerns. The proposed delisting aligns with broa
Private equity firms CVC and GBL launched a €10.7 billion cash bid to take over Italian pharmaceutical group Recordati, offering €51.29 per share. The controlling shareholder has agreed to tender its
ChemBrief